CHRNB2 Protein — Nicotinic Receptor Beta 2 Subunit

Migration, Crosslink

📖

CHRNB2 Protein — Nicotinic Receptor Beta 2 Subunit

active

wiki page Created: 2026-04-02T07:19:12 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-chrnb2-protein

📖 Wiki Page

protein2904 wordssynced 2026-04-02

CHRNB2 Protein — Nicotinic Acetylcholine Receptor Beta 2 Subunit

Overview

CHRNB2 encodes the beta-2 (β2) subunit of neuronal nicotinic acetylcholine receptors (nAChRs), which are pentameric ligand-gated ion channels critical for fast cholinergic synaptic transmission in the central and peripheral nervous systems. The β2 subunit is a defining component of the most abundant nicotinic receptor subtype in the mammalian brain—the α4β2* receptor—where it plays essential roles in cognitive processes, attention, learning, memory, reward signaling, and motor control. Dysregulation of CHRNB2-containing receptors has been strongly implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), epilepsy, nicotine addiction, and various neuropsychiatric disorders[@gotti2006][@lloyd2006].

The neuronal nAChRs belong to the Cys-loop receptor superfamily, which also includes GABA_A, glycine, and 5-HT3 receptors. Unlike muscle-type nAChRs found at the neuromuscular junction, neuronal nAChRs containing the β2 subunit are primarily expressed in the brain and autonomic ganglia, where they modulate neurotransmission and neuronal excitability. The α4β2 receptor (\"\\" denotes possible inclusion of other subunits) is the predominant subtype in the hippocampus, cortex, thalamus, and basal ganglia—brain regions critical for cognition, movement, and reward processing[@han2007].

...

CHRNB2 Protein — Nicotinic Acetylcholine Receptor Beta 2 Subunit

Overview

CHRNB2 encodes the beta-2 (β2) subunit of neuronal nicotinic acetylcholine receptors (nAChRs), which are pentameric ligand-gated ion channels critical for fast cholinergic synaptic transmission in the central and peripheral nervous systems. The β2 subunit is a defining component of the most abundant nicotinic receptor subtype in the mammalian brain—the α4β2* receptor—where it plays essential roles in cognitive processes, attention, learning, memory, reward signaling, and motor control. Dysregulation of CHRNB2-containing receptors has been strongly implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), epilepsy, nicotine addiction, and various neuropsychiatric disorders[@gotti2006][@lloyd2006].

The neuronal nAChRs belong to the Cys-loop receptor superfamily, which also includes GABA_A, glycine, and 5-HT3 receptors. Unlike muscle-type nAChRs found at the neuromuscular junction, neuronal nAChRs containing the β2 subunit are primarily expressed in the brain and autonomic ganglia, where they modulate neurotransmission and neuronal excitability. The α4β2 receptor (\"\\" denotes possible inclusion of other subunits) is the predominant subtype in the hippocampus, cortex, thalamus, and basal ganglia—brain regions critical for cognition, movement, and reward processing[@han2007].

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">CHRNB2 Protein</th></tr>
<tr><td>Protein Name</td><td>nAChR β2 Subunit</td></tr>
<tr><td>Gene Symbol</td><td>CHRNB2</td></tr>
<tr><td>UniProt ID</td><td>[P17787](https://www.uniprot.org/uniprot/P17787)</td></tr>
<tr><td>PDB IDs</td><td>5KXI, 6CNG, 7K7Y</td></tr>
<tr><td>Chromosome</td><td>1q21.3</td></tr>
<tr><td>NCBI Gene ID</td><td>[1144](https://www.ncbi.nlm.nih.gov/gene/1144)</td></tr>
<tr><td>Protein Family</td><td>Cys-loop receptor family</td></tr>
<tr><td>Structure</td><td>Pentameric ligand-gated ion channel</td></tr>
<tr><td>Subcellular Location</td><td>Plasma membrane</td></tr>
<tr><td>Molecular Weight</td><td>~57 kDa (glycosylated)</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Molecular Biology and Structure

Gene Organization and Expression

The CHRNB2 gene is located on chromosome 1q21.3 and spans approximately 6.5 kb. It consists of 6 exons encoding a protein of 493 amino acids. CHRNB2 is expressed predominantly in the central nervous system, with highest levels in:

Hippocampus: CA1-CA3 regions and dentate gyrus
Cerebral cortex: Layer I-VI, particularly layer IV
Thalamus: Relay nuclei and intralaminar nuclei
Basal ganglia: Striatum, nucleus accumbens, substantia nigra pars compacta
Brainstem: Pedunculopontine nucleus, laterodorsal tegmental nucleus
Autonomic ganglia: Superior cervical ganglion, nodose ganglion

The developmental expression pattern shows that CHRNB2 subunit expression increases during postnatal development, peaking in early adulthood and declining with aging—paralleling the trajectory of cognitive function[@han2007][@taly2015].

Receptor Architecture

Neuronal nAChRs are pentameric assemblies composed of five subunits arranged around a central ion channel pore. Each subunit contains:

N-terminal extracellular domain (~210 residues): Contains the acetylcholine binding site at subunit interfaces

Transmembrane domain (~140 residues): Four α-helices (M1-M4), with M2 forming the ion channel pore

Intracellular loop (~60 residues): Between M3 and M4, contains trafficking signals

C-terminal extracellular domain (~20 residues): Short cytoplasmic tail

The β2 subunit contributes to the receptor's pharmacological profile and determines channel properties such as conductance, desensitization kinetics, and calcium permeability. When combined with α4 subunits, the resulting α4β2 receptor exhibits:

| Property | Value |
|----------|-------|
| Single-channel conductance | 30-40 pS |
| Mean open time | 1-5 ms |
| Desensitization time constant | 100 ms to several seconds |
| Calcium permeability | 1.5-5% of total current |
| Reversal potential | ~0 mV (Na+ equilibrium) |

Subunit Composition and Diversity

The β2 subunit can combine with various α subunits to form functionally distinct receptors:

| Receptor Subtype | Stoichiometry | Brain Region | Key Functions |
|------------------|---------------|---------------|---------------|
| α4β2* (predominant) | (α4)₂(β2)₃ | Hippocampus, cortex, thalamus | Cognitive processes, attention |
| α3β2 | (α3)₂(β2)₃ | Autonomic ganglia | Peripheral cholinergic signaling |
| α2β2 | (α2)₂(β2)₃ | Hippocampus, cortex (lower expression) | Similar to α4β2 |
| α5-β2 | (α4)₂(β2)₂α5 | Cortex, hippocampus | Enhanced calcium permeability |
| β2-δ/ε | (β2)₃(δ or ε) | Neuromuscular junction (mutant) | Not brain-localized |

The asterisks (*) in nomenclature indicates that additional subunits (such as α5 or β3) may be incorporated into the receptor complex, altering its pharmacological and physiological properties.

Structural Insights from Cryo-EM

Recent cryo-electron microscopy studies have provided atomic-resolution structures of α4β2 nAChRs:

5KXI: Human α4β2 receptor in apo state
6CNG: Human α4β2 with agonist bound
7K7Y: Full receptor in multiple conformational states

These structures reveal the conformational changes underlying channel activation and desensitization, providing templates for structure-based drug design. The agonist-binding site is located at the extracellular interface between α4 and β2 subunits, with key residues determining agonist potency and efficacy.

Normal Physiological Functions

Cholinergic Neurotransmission

CHRNB2-containing nAChRs mediate fast excitatory neurotransmission at cholinergic synapses throughout the brain. Key functions include:

Presynaptic modulation: nAChRs on presynaptic terminals regulate release of glutamate, GABA, dopamine, norepinephrine, and acetylcholine itself

Postsynaptic excitation: Postsynaptic nAChRs mediate fast depolarizing responses to acetylcholine

Neuromodulation: Through presynaptic effects, β2-containing receptors modulate the activity of multiple transmitter systems

Cognitive Processes

The α4β2* receptor is critically involved in higher cognitive functions:

Attention: Nicotinic agonists enhance attentional processing; β2 subunit is essential for this effect
Learning and memory: Hippocampal α4β2 receptors contribute to spatial memory consolidation
Working memory: Prefrontal cortex nAChRs support working memory operations
Executive function: Frontal cortex receptors contribute to cognitive flexibility

Reward and Addiction

The mesolimbic dopamine pathway is modulated by β2-containing receptors:

Ventral tegmental area (VTA): α4β2 receptors on VTA neurons regulate dopamine release to nucleus accumbens
Nicotine addiction: β2 subunit is required for nicotine self-administration in rodents
Genetic variants: CHRNB2 polymorphisms are associated with nicotine dependence susceptibility

Motor Control

In basal ganglia circuits, β2-containing receptors influence motor function:

Striatal modulation: nAChRs on striatal interneurons and terminals regulate movement
Substantia nigra: Presynaptic receptors on dopaminergic neurons modulate nigrostriatal signaling
Motor learning: Sensorimotor integration involves β2 receptor signaling

Role in Alzheimer's Disease

Cholinergic Hypothesis and Receptor Loss

The cholinergic hypothesis of AD posits that loss of basal forebrain cholinergic neurons and subsequent decline in acetylcholine signaling contributes to cognitive deficits. CHRNB2-containing receptors are primary targets of this degeneration:

Receptor density reduction: Post-mortem studies show 40-70% reduction in α4β2 binding in AD cortex and hippocampus
Correlation with cognitive decline: α4β2 receptor loss correlates with impaired memory performance
Selective vulnerability: β2-containing receptors are more vulnerable than α7 receptors

Amyloid-Beta Interactions

Amyloid-beta (Aβ) peptides interact directly and indirectly with α4β2 receptors:

Direct binding: Aβ1-42 binds to nAChRs with low micromolar affinity, potentially functioning as an antagonist
Receptor internalization: Aβ promotes internalization of α4β2 receptors
Calcium dysregulation: Aβ-induced calcium dysregulation is exacerbated through nAChR-mediated calcium influx
Synaptic dysfunction: Aβ-induced synaptic deficits are partially mediated through nAChR modulation

The relationship between Aβ and nAChRs is complex—while acute activation may be protective, chronic Aβ exposure leads to receptor dysfunction and downregulation[@dineley2020][@yang2017].

Therapeutic Implications for AD

Targeting α4β2 receptors remains a therapeutic strategy for AD:

| Approach | Agent | Status | Mechanism |
|----------|-------|--------|----------|
| AChE inhibitors | Donepezil, Rivastigmine | Approved | Increase synaptic ACh to activate receptors |
| Direct agonists | TC-1734 | Phase II | Selective α4β2 activation |
| Positive allosteric modulators | NS-1738 | Preclinical | Enhance agonist efficacy |
| Antagonists | Mecamylamine | Phase II | Prevent receptor desensitization |

Nicotine and nicotinic agonists have demonstrated cognitive benefits in AD patients, though side effects limit clinical utility. Newer approaches focus on partial agonists with improved safety profiles and allosteric modulators that preserve temporal signaling patterns[@newhouse2012][@peters2013][@usluer2024].

Prodromal and Early Stage Changes

Recent research reveals that nAChR dysfunction begins in prodromal AD:

MCI subjects: Reduced α4β2 binding in cortex and hippocampus
Biomarkers: CSF nAChR levels may serve as early biomarkers
Intervention window: Early intervention may prevent downstream degeneration

Role in Parkinson's Disease

Nigrostriatal Degeneration and Receptor Loss

In PD, the loss of dopaminergic neurons in substantia nigra pars compacta leads to secondary changes in nAChR expression:

Striatal receptor changes: α4β2 binding is reduced in PD striatum
Substantia nigra: Loss of nAChR-positive dopaminergic neurons
Compensatory mechanisms: Early stages may show receptor upregulation

Nicotine as a Neuroprotective Agent

Epidemiological studies suggest that nicotine consumption (via tobacco) reduces PD risk:

Inverse correlation: Smoking history correlates with reduced PD incidence
Neuroprotective mechanisms: nAChR activation may protect dopaminergic neurons
Anti-inflammatory effects: Cholinergic anti-inflammatory pathway via α7 and β2 receptors

Motor and Non-Motor Symptoms

CHRNB2-containing receptors influence both motor and non-motor PD symptoms:

Motor complications: Levodopa-induced dyskinesias involve nAChR dysfunction
Cognitive impairment: PD dementia involves nAChR loss similar to AD
Autonomic dysfunction: Peripheral β2 receptors affect autonomic regulation

Therapeutic Approaches for PD

| Strategy | Agent | Rationale |
|----------|-------|----------|
| Nicotine replacement | Patch, gum | Neuroprotection, motor symptom improvement |
| α4β2 agonists | ABT-089, TC-1734 | Cognitive and motor benefits |
| Combination therapy | Nicotine + dopaminergic drugs | Enhanced efficacy |
| Allosteric modulators | Novel compounds | Improved safety profile |

Clinical trials of nicotine in PD have shown mixed results, with some benefit for motor symptoms but limited overall efficacy. Novel selective agonists and positive allosteric modulators are in development[@bordia2015][@hernandez2022].

Role in Epilepsy

CHRNB2 Mutations and ADNFLE

Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE) was the first human disease linked to neuronal nAChR mutations. CHRNB2 mutations identified in ADNFLE include:

V287M: First identified mutation, causes gain-of-function
V287L: Similar gain-of-function phenotype
I296M: Increased channel activity
S299L: Enhanced agonist sensitivity
L301V: Altered desensitization kinetics

These mutations cause increased channel activity in response to acetylcholine, leading to neuronal hyperexcitability, particularly during sleep when cholinergic tone is high. The seizures occur predominantly during non-REM sleep, reflecting the physiological activation of cholinergic neurons during this state[@steinlein2014][@barlow2020].

Mechanisms of Epileptogenesis

Gain-of-function CHRNB2 mutations lead to epilepsy through:

Enhanced excitatory drive: Increased nAChR currents depolarize neurons

Network hypersynchrony: Excessive cholinergic signaling promotes seizure-like activity

Cortical excitability: Altered thalamocortical circuit function

GABAergic modulation: Secondary effects on inhibitory circuits

Therapeutic Implications

CHRNB2-related epilepsy has been treated with:

Carbamazepine: Sodium channel blocker, first-line therapy
Topiramate: Multiple mechanisms including nAChR antagonism
Zonisamide: Broader efficacy in ADNFLE
Nicotinic antagonists: Mecamylamine (experimental)

Understanding CHRNB2 mutations has provided insights into the role of cholinergic signaling in seizure generation and potential therapeutic targets.

Role in Neuroinflammation

Cholinergic Anti-Inflammatory Pathway

The cholinergic anti-inflammatory pathway represents a neuroimmune regulatory mechanism:

Vagus nerve: Acetylcholine release inhibits peripheral cytokine production
α7 nAChR: Primary mediator in macrophages, but β2 receptors also contribute
Microglial modulation: nAChR activation alters microglial morphology and function
TNF-α regulation: Nicotinic signaling reduces pro-inflammatory cytokine release

Implications for Neurodegeneration

Chronic neuroinflammation is a hallmark of AD, PD, and ALS:

Microglial activation: β2 receptors modulate microglial phenotype
Cytokine production: nAChR signaling reduces inflammatory mediators
Therapeutic potential: Nicotinic agonists may reduce neuroinflammation

Genetic Variants and Neuropsychiatric Disorders

CHRNB2 Polymorphisms

Genome-wide association studies (GWAS) have identified CHRNB2 variants associated with:

Nicotine dependence: Multiple SNPs correlate with smoking behavior
Schizophrenia: Some variants increase risk
Attention-deficit/hyperactivity disorder (ADHD): Association with impulsivity
Major depressive disorder: Risk variants identified in some populations
Cognitive performance: SNP effects on memory and processing speed

Copy Number Variants

Rare CHRNB2 copy number variants have been reported in:

Intellectual disability: Deletions encompassing CHRNB2
Autism spectrum disorders: Some patients carry rare variants
Epilepsy: Duplications may increase seizure risk

Genotype-Phenotype Correlations

| Variant Type | Phenotype | Mechanism |
|--------------|-----------|-----------|
| Missense (gain-of-function) | ADNFLE | Increased channel activity |
| Missense (loss-of-function) | Cognitive deficits | Reduced signaling |
| Promoter variants | Nicotine dependence | Altered expression |
| Rare deletions | Neurodevelopmental disorders | Haploinsufficiency |

Therapeutic Targeting

Approved Drugs Targeting nAChRs

| Drug | Target | Indication | Mechanism |
|------|--------|-----------|-----------|
| Nicotine | α4β2, α3β4 | Smoking cessation | Partial agonist |
| Varenicline | α4β2, α3β2 | Smoking cessation | Partial agonist |
| Cytisine | α4β2, α3β4 | Smoking cessation (Europe) | Partial agonist |
| Donepezil | AChE → α4β2 | AD | Indirect activation |
| Rivastigmine | AChE → α4β2 | AD, PDD | Indirect activation |
| Galantamine | AChE → α4β2 | AD | Indirect activation + PAM |

Drugs in Development

| Agent | Company | Stage | Target |
|-------|---------|-------|--------|
| TC-1734 | Targacept | Phase II | α4β2 agonist |
| AZD-0327 | AstraZeneca | Preclinical | α4β2 agonist |
| NS-1738 | Unknown | Preclinical | α4β2 PAM |
| ABT-594 | Abbott | Discontinued | α4β2 agonist |

Side Effects and Challenges

Nicotinic agonist development faces challenges:

Cardiovascular effects: Tachycardia, hypertension
Gastrointestinal: Nausea, vomiting
Central effects: Insomnia, vivid dreams, headache
Seizure risk: Particularly in susceptible individuals
Addiction potential: Especially with high-efficacy agonists

Partial agonists (varenicline, cytisine) offer improved safety profiles with reduced side effects.

Animal Models

Knockout Mice

CHRNB2 knockout mice (Chrnb2⁻/⁻) have been instrumental in understanding receptor function:

Cognitive deficits: Impaired working memory and attention
Reduced nicotine response: No nicotine-induced dopamine release
Altered synaptic plasticity: Impaired LTP in hippocampus
Protection from nicotine addiction: No nicotine self-administration
Neurochemical changes: Reduced striatal dopamine, altered GABA signaling

Transgenic Models

Conditional and inducible transgenic models allow:

Region-specific rescue: Restoration of β2 in specific brain regions
Temporal control: Inducible expression to study developmental effects
Mutation modeling: Human disease mutations in mice

Phenotype Summary

| Model | Key Phenotype | Research Utility |
|-------|---------------|------------------|
| Chrnb2⁻/⁻ | Cognitive deficits, no nicotine response | Receptor function |
| Chrnb2⁺/⁻ | Partial deficits, enhanced vulnerability | Haploinsufficiency |
| Humanized | Human CHRNB2 expression | Drug testing |
| ADNFLE mutant | Seizure phenotype | Epilepsy mechanisms |

Biomarkers and Diagnostic Applications

PET Imaging

Radioligands for imaging β2-containing receptors:

¹²³I-iodinated ligands: SPECT imaging in research
¹⁸F-labeled ligands: PET imaging, limited availability
²⁸S-labeled tropanes: High-affinity imaging agents

CSF Biomarkers

Emerging biomarkers include:

nAChR levels: Reduced in AD and PD CSF
Soluble receptor fragments: Potential disease markers
Autoantibodies: Anti-nAChR antibodies in some disorders

Genetic Testing

Clinical genetic testing for CHRNB2:

ADNFLE diagnosis: Confirmatory testing for epilepsy
Carrier testing: Family member risk assessment
Pharmacogenomics: Predicting nicotine dependence risk

Research Directions and Future Perspectives

Novel Therapeutic Strategies

Subunit-selective agonists: Targeting specific receptor configurations

Allosteric modulators: Positive and negative modulators

Signal compartmentation: Preserving physiological signaling patterns

Combination therapies: nAChR agonists with other mechanisms

Biomarker Development

Early detection: Identifying at-risk individuals
Treatment response: Predicting therapeutic efficacy
Disease progression: Monitoring neurodegeneration

Gene Therapy Approaches

Viral vector delivery: Direct CNS delivery of CHRNB2
CRPR editing: Correcting pathogenic mutations
Regulated expression: Inducible systems for controlled therapy

Key Research Findings

1. Discovery of ADNFLE Mutations

Steinlein and colleagues identified the first CHRNB2 mutation (V287M) causing autosomal dominant nocturnal frontal lobe epilepsy, establishing a direct link between neuronal nAChR dysfunction and human epilepsy. This discovery revolutionized understanding of genetic epilepsy mechanisms.

2. Cryo-EM Structure Determination

Morales-Perez and colleagues solved the first atomic-resolution structure of the human α4β2 nAChR, providing unprecedented insights into the structural basis for agonist binding, channel gating, and allosteric modulation.

3. Role in Nicotine Addiction

The critical role of β2-containing receptors in nicotine reward was demonstrated through knockout mice studies, showing that CHRNB2 deletion eliminates nicotine self-administration and dopamine release in the nucleus accumbens.

4. Cognitive Enhancement in AD

Multiple clinical trials have demonstrated that nicotinic agonists can improve cognitive function in AD patients, validating α4β2 receptors as therapeutic targets for dementia.

[CHRNB2 Gene](/genes/chrnb2)
[Nicotinic Acetylcholine Receptors](/entities/nicotinic-receptors)
[Cholinergic Signaling in Neurodegeneration](/mechanisms/cholinergic-signaling-neurodegeneration)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Epilepsy](/diseases/epilepsy)
[Acetylcholinesterase Inhibitors](/therapeutics/acetylcholinesterase-inhibitors)

External Links

[UniProt: CHRNB2 - P17787](https://www.uniprot.org/uniprot/P17787)
[NCBI Gene: CHRNB2](https://www.ncbi.nlm.nih.gov/gene/1144)
[Ensembl: CHRNB2](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137336)
[PDB: 5KXI (α4β2 nAChR)](https://www.rcsb.org/structure/5KXI)
[IUPHAR: nAChR Subunits](https://www.guidetopharmacology.org/GRAC/FamilyIntroductionForward?familyId=8)
[GeneCards: CHRNB2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CHRNB2)
[OMIM: CHRNB2](https://www.omim.org/entry/118507)

References

[Han et al., Distribution of nicotinic receptors in the human brain and clinical relevance (2007)](https://pubmed.ncbi.nlm.nih.gov/17207768/)

[Gotti et al., Nicotinic acetylcholine receptors in the brain: from circuitry to function (2006)](https://pubmed.ncbi.nlm.nih.gov/16771899/)

[Lloyd & Williams, Neuronal nicotinic receptors as drug targets (2006)](https://pubmed.ncbi.nlm.nih.gov/16678550/)

[Newhouse et al., Nicotinic acetylcholine receptor agonists for neuroprotection (2012)](https://pubmed.ncbi.nlm.nih.gov/22639998/)

[Peters et al., Nicotinic receptors in aging and dementia (2013)](https://pubmed.ncbi.nlm.nih.gov/23571419/)

[Bordia et al., Nicotinic receptors as targets for Parkinson's disease therapy (2015)](https://pubmed.ncbi.nlm.nih.gov/25576122/)

[Lombardo & Maskos, Alpha4beta2 nicotinic receptors in CNS disorders (2018)](https://pubmed.ncbi.nlm.nih.gov/30649666/)

[Yang et al., Role of nicotinic acetylcholine receptors in Alzheimer's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/27569905/)

[Maurice et al., Neuronal nicotinic acetylcholine receptor dysfunction in prodromal Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34039357/)

[Barlow et al., Beta2 subunit-containing nicotinic receptors in the pathogenesis of epilepsy (2020)](https://pubmed.ncbi.nlm.nih.gov/31759022/)

[Dineley et al., Beta-amyloid peptide and nicotinic acetylcholine receptors (2020)](https://pubmed.ncbi.nlm.nih.gov/32816084/)

[Hernandez et al., Nicotinic receptor modulation for neuroprotection in Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35051416/)

[Yang et al., Alpha4beta2 nAChR agonists for cognitive enhancement in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/34742981/)

[Kawasaki et al., Neuronal nicotinic receptors in cognitive decline: new therapeutic strategies (2024)](https://pubmed.ncbi.nlm.nih.gov/38097342/)

[Usluer et al., α4β2 nicotinic acetylcholine receptor agonists in Alzheimer's disease trials (2024)](https://pubmed.ncbi.nlm.nih.gov/38647328/)

[Zhang et al., CHRNB2 variants associated with neuropsychiatric disorders (2023)](https://pubmed.ncbi.nlm.nih.gov/36539652/)

[Steinlein, Genetic disorders causing epilepsy: nicotinic acetylcholine receptor mutations (2014)](https://pubmed.ncbi.nlm.nih.gov/25144149/)

[Xu et al., Nicotinic acetylcholine receptors and microglia in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31213987/)

[Zappettini et al., Cholinergic anti-inflammatory pathway and nicotinic receptors (2022)](https://pubmed.ncbi.nlm.nih.gov/35030486/)

[Taly et al., Neuronal nicotinic acetylcholine receptors: structure, function and pathology (2015)](https://pubmed.ncbi.nlm.nih.gov/25753741/)

📖 View canonical wiki page →

Related Entities

CHRNB2PROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-chrnb2-protein
kg_node_id	CHRNB2PROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-182d5bc28b90
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-chrnb2-protein'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

70%

Debates

0

Incoming

14

Outgoing

15

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

CHRNB2 Protein — Nicotinic Receptor Beta 2 Subunit

CHRNB2 Protein — Nicotinic Acetylcholine Receptor Beta 2 Subunit

Overview

CHRNB2 Protein — Nicotinic Acetylcholine Receptor Beta 2 Subunit

Overview

Molecular Biology and Structure

Gene Organization and Expression

Receptor Architecture

Subunit Composition and Diversity

Structural Insights from Cryo-EM

Normal Physiological Functions

Cholinergic Neurotransmission

Cognitive Processes

Reward and Addiction

Motor Control

Role in Alzheimer's Disease

Cholinergic Hypothesis and Receptor Loss

Amyloid-Beta Interactions

Therapeutic Implications for AD

Prodromal and Early Stage Changes

Role in Parkinson's Disease

Nigrostriatal Degeneration and Receptor Loss

Nicotine as a Neuroprotective Agent

Motor and Non-Motor Symptoms

Therapeutic Approaches for PD

Role in Epilepsy

CHRNB2 Mutations and ADNFLE

Mechanisms of Epileptogenesis

Therapeutic Implications

Role in Neuroinflammation

Cholinergic Anti-Inflammatory Pathway

Implications for Neurodegeneration

Genetic Variants and Neuropsychiatric Disorders

CHRNB2 Polymorphisms

Copy Number Variants

Genotype-Phenotype Correlations

Therapeutic Targeting

Approved Drugs Targeting nAChRs

Drugs in Development

Side Effects and Challenges

Animal Models

Knockout Mice

Transgenic Models

Phenotype Summary

Biomarkers and Diagnostic Applications

PET Imaging

CSF Biomarkers

Genetic Testing

Research Directions and Future Perspectives

Novel Therapeutic Strategies

Biomarker Development

Gene Therapy Approaches

Key Research Findings

1. Discovery of ADNFLE Mutations

2. Cryo-EM Structure Determination

3. Role in Nicotine Addiction

4. Cognitive Enhancement in AD

Related Pages

External Links

References

💬 Discussion